Skip to content
Menu

JP Morgan Maintains Overweight on Edgewise Therapeutics, Raises Price Target to $69

Benzinga Newsdesk 3 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

JP Morgan analyst Tessa Romero maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Overweight and raises the price target from $60 to $69.

JP Morgan analyst Tessa Romero maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Overweight and raises the price target from $60 to $69.

Read at benzinga.com